Novartis Shutdown Could Cause Supply Problems for Endo
In a press release issued by Endo Pharmaceuticals, the company expressed concerns that the halting of production at Novartis Consumer Health’s manufacturing facility in Lincoln, NE—coming on the heels of production and packaging problems—will lead to short-term supply constraints for its pharmaceutical offerings. Specifically, Endo representatives belive shipments of its OPANA ER semi-synthetic opioid analgesic might be affected, along with certain other Endo analgesic products produced at the plant.
"We are working collaboratively with the FDA to minimize the disruption to patients currently on therapy. Given existing inventories, the expected restart of Novartis production and our ability to shift production to other facilities we believe the supply constraints of our products should be limited," said Julie McHugh, chief operating officer of Endo Pharmaceuticals.
Source: Endo Pharmaceuticals